Caribou Biosciences is preparing to widen access to allogeneic CAR T by moving toward a pivotal Phase III trial, supported by its genome editing approach and product optimization. The company said its allogeneic CAR T cells have shown efficacy and durability comparable to approved autologous CAR T in specific blood cancers, with an inventory-based donor matching strategy. Caribou’s emphasis on off-the-shelf manufacturing aims to reduce delays inherent to bespoke autologous production and to address the gap where many eligible patients never receive CAR T due to disease progression, referral bottlenecks, and socioeconomic barriers. The planned pivotal step signals a continued push to convert cell therapy logistics into a scalable model for broader patient access.